Leuco-methylthioninium

From Ganfyd

Jump to: navigation, search

Contents

Introduction

A stabilised form of methylene blue which is a first-in-class tau aggregation inhibitor being developed for the treatment of mild to moderate Alzheimer's disease and behavioural variant frontotemporal dementia. Postulated to act by preventing the formation and spread of neurofibrillary tangles. Phase III trials should report in 2015.

Clinical Use

Indications

Administration

Oral 150mg or 250mg twice daily

Clinical Issues

Contra-indications

Cautions and Interactions

Side effects

  • Blue dye

Special advice

Pharmacology

Enzyme converted in the stomach from the stabilised, reduced form of charged leuco-methylthioninium chloride to uncharged leuco-methylthioninium prior to absorption.

Personal tools